ROCHE HOLDING LTD 4
4 · Entrada Therapeutics, Inc. · Filed Nov 4, 2021
Insider Transaction Report
Form 4
ROCHE HOLDING LTD
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2021-11-02−318,140→ 0 total(indirect: See Footnote)→ Common Stock (318,140 underlying) - Conversion
Common Stock
2021-11-02+318,140→ 2,813,525 total(indirect: See Footnote) - Conversion
Series A Preferred Stock
2021-11-02−2,495,385→ 0 total(indirect: See Footnote)→ Common Stock (2,495,385 underlying) - Conversion
Common Stock
2021-11-02+2,495,385→ 2,495,385 total(indirect: See Footnote)
Footnotes (2)
- [F1]Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date.
- [F2]Represents shares held by Roche Finance Ltd ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.